Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 15th total of 2,680,000 shares. Approximately 7.4% of the company’s stock are short sold. Based on an average trading volume of 286,800 shares, the short-interest ratio is currently 11.8 days.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds have recently bought and sold shares of ATXS. FMR LLC increased its stake in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. Vestal Point Capital LP lifted its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares during the period. Nantahala Capital Management LLC acquired a new stake in Astria Therapeutics in the 2nd quarter worth about $6,142,000. Redmile Group LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter valued at about $3,423,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Astria Therapeutics during the 2nd quarter worth about $2,561,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on ATXS. Oppenheimer increased their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Monday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Trading Down 3.2 %

Shares of ATXS traded down $0.25 during trading hours on Friday, reaching $7.50. The company had a trading volume of 237,439 shares, compared to its average volume of 327,213. Astria Therapeutics has a 12-month low of $6.95 and a 12-month high of $16.90. The company has a market capitalization of $423.23 million, a price-to-earnings ratio of -3.59 and a beta of 0.70. The firm has a 50 day simple moving average of $9.52 and a 200-day simple moving average of $10.63.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.